S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
The 3-Stock Retirement Blueprint (Ad)
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NASDAQ:CLBS

Caladrius Biosciences - CLBS Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
$0.43
$8.55
52-Week Range
N/A
Volume
466,373 shs
Average Volume
522,308 shs
Market Capitalization
$26.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.00

Caladrius Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
∞ Upside
$90.00 Price Target
Short Interest
Healthy
0.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.41mentions of Caladrius Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.43) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

435th out of 1,093 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

7th out of 12 stocks

CLBS stock logo

About Caladrius Biosciences (NASDAQ:CLBS) Stock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLBS Stock News Headlines

CLBS Caladrius Biosciences, Inc.
See More Headlines

Receive CLBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLBS Company Calendar

Last Earnings
11/04/2021
Today
10/01/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLBS
Employees
27
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$90.00
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$90.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.54 per share

Miscellaneous

Free Float
59,250,000
Market Cap
$26.05 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Dr. David J. Mazzo B.A. (Hons) (Age 65)
    B.Sc. (Hons.), M.Sc., Ph.D., Pres, CEO & Director
    Comp: $957.69k
  • Dr. Kristen K. Buck M.D. (Age 48)
    Exec. VP of R&D and Chief Medical Officer
    Comp: $825k
  • Mr. James Nisco
    VP of Fin. & Treasury
  • Mr. Gregory S. Berkin
    Chief Information Officer
  • Mr. John D. Menditto
    VP of Investor Relations & Corp. Communications
  • Eric Powers
    Director of Communications and Marketing
  • Ms. Gail Holler (Age 63)
    VP of HR
  • Dr. Ian Zhang Ph.D. (Age 57)
    MBA, Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc
  • Dr. William K. Sietsema Ph.D. (Age 66)
    VP of Global Regulatory Affairs













CLBS Stock - Frequently Asked Questions

Should I buy or sell Caladrius Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CLBS shares.
View CLBS analyst ratings
or view top-rated stocks.

What is Caladrius Biosciences' stock price forecast for 2022?

1 brokerages have issued twelve-month price targets for Caladrius Biosciences' shares. Their CLBS share price forecasts range from $90.00 to $90.00. On average, they expect the company's share price to reach $90.00 in the next twelve months.
View analysts price targets for CLBS
or view top-rated stocks among Wall Street analysts.

When is Caladrius Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CLBS earnings forecast
.

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.95) by $0.15. During the same period in the previous year, the firm posted ($4.35) earnings per share.

When did Caladrius Biosciences' stock split?

Caladrius Biosciences's stock reverse split before market open on Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is David J. Mazzo's approval rating as Caladrius Biosciences' CEO?

1 employees have rated Caladrius Biosciences Chief Executive Officer David J. Mazzo on Glassdoor.com. David J. Mazzo has an approval rating of 100% among the company's employees. This puts David J. Mazzo in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 53.0% of employees surveyed would recommend working at Caladrius Biosciences to a friend.

What other stocks do shareholders of Caladrius Biosciences own?
What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How do I buy shares of Caladrius Biosciences?

Shares of CLBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Caladrius Biosciences make?

Caladrius Biosciences (NASDAQ:CLBS) has a market capitalization of $0.00. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The official website for the company is www.caladrius.com. The biotechnology company can be reached via phone at (908) 842-0100, via email at jmenditto@caladrius.com, or via fax at 646-514-7787.

This page (NASDAQ:CLBS) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.